In a quiet but consequential regulatory shift, New Zealand has become only the second nation to formally authorize MDMA-assisted therapy for severe PTSD, following Australia's lead while the United States and most of the world remain hesitant. The decision reflects a growing willingness among some governments to reconsider the clinical potential of substances long confined to prohibition, particularly for conditions that have resisted conventional treatment. For those living with trauma that ordinary medicine has failed to reach, this approval opens a carefully guarded door.